17,261 trials
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities · Adult Acute Myeloid Leukemia With Del(5q) · Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Primary: Number of Participants With Response — 1; 4; 5; 3 Participants
Invasive Breast Cancer
Primary: Correlation Coefficient Between FFNP Uptake and Allred Score — 0.3215 correlation coefficient (rho) — p=0.1347
Sarcoma
Primary: Percentage of Participants in Objective Response at 6 Months — 0.0; 0.0; 0.0; 6.7 percentage of participants
Rectal Cancer
Primary: Neoadjuvant Response (NAR) Score — 9.31 Calculated score
Advanced or Metastatic Solid Tumors
Primary: Phase 1: Number of Participants With One or More Treatment Emergent Adverse Events (TEAEs) — 3; 6; 33; 19 Participants
Arthroplasty, Replacement, Knee · Arthroplasty, Replacement, Hip
Primary: Blood Plasma TXA Concentration - Total Body Clearance — 58.0; 116 mL/min
Vertigo · Dizziness
Primary: VRT vs. ED SOC Six-Category Diagnosis Accuracy (Primary Analysis-eligible Participants, Two-arm Comparison) — 24; 18; 33; 38 Participants
Metastatic Melanoma
Primary: Disease Assessment for Objective Response Rate — 4; 23; 1; 25 Participants
Suppression of Ovulation
Primary: Number of Days Bleeding is Reported. — 34.0; 42.1; 39.8; 14.7 Days
Peripheral Arterial Disease
Primary: Walking Distance — 375; 411; 405; 425 meters — p=0.38
Cholestatic Liver Disease
Primary: Incidence of Treatment-Emergent Adverse Events — 36; 12; 9; 4 Participants
Sleep Apnea Syndromes · Insomnia Disorder · Stress Disorders, Post-Traumatic
Primary: World Health Organization Quality of Life (WHOQOL-BREF) — 11.26; 9.75; 12.78; 10.84 units on a scale
Postpartum Depression
Primary: Edinburgh Postnatal Depression Scale (EPDS) Mean Total Score — 3.75; 3; 0; 1.14 Units on a scale
Hookworm Infections
Primary: Detectable Hookworm Infection — 0; 0; 0; 0 Participants
Metastatic Colorectal Cancer
Primary: Number of Participants With Response — 0; 0; 1; 1 Participants